These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24687034)

  • 21. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
    Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carboquone combined with methotrexate and 5-fluorouracil for recurrent and advanced ovarian cancer.
    Mäenpää JU; Heinonen E; Karnani P; Kauppila A; Kuoppala T; Salmi T; Sipilä P; Nieminen U
    Eur J Cancer; 1993; 29A(11):1633. PubMed ID: 8217372
    [No Abstract]   [Full Text] [Related]  

  • 23. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
    Markman M
    Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
    [No Abstract]   [Full Text] [Related]  

  • 24. Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer.
    Sood AK; Coleman RL; Ellis LM
    J Clin Oncol; 2012 Feb; 30(4):345-7. PubMed ID: 22184398
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment for recurrent ovarian cancer. A report of 2 cases.
    Maxwell AM; Jordaan JP
    S Afr Med J; 1987 Feb; 71(3):180. PubMed ID: 3810370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of pegylated liposomal doxorubicin and carboplatin with paclitaxel and carboplatin in the treatment of patients with late recurrence of platin-sensitive ovarian carcinoma].
    Zvaríková M
    Klin Onkol; 2011; 24(6):475-6. PubMed ID: 22268244
    [No Abstract]   [Full Text] [Related]  

  • 27. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platinum based chemotherapy to treat recurrent Sertoli-Leydig cell ovarian carcinoma during pregnancy.
    Tomlinson MW; Treadwell MC; Deppe G
    Eur J Gynaecol Oncol; 1997; 18(1):44-6. PubMed ID: 9061323
    [No Abstract]   [Full Text] [Related]  

  • 29. [The treatment of refractory ovarian cancer].
    Shparyk IaV; Tomych MV
    Lik Sprava; 1996; (10-12):41-7. PubMed ID: 9138811
    [No Abstract]   [Full Text] [Related]  

  • 30. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
    Harter P; Hilpert F; Mahner S; Heitz F; Pfisterer J; du Bois A
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):81-8. PubMed ID: 20014888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
    Lindemann K; Kristensen G; Mirza MR; Davies L; Hilpert F; Romero I; Ayhan A; Burges A; Rubio MJ; Raspagliesi F; Huizing M; Creemers GJ; Lykka M; Lee CK; Gebski V; Pujade-Lauraine E
    Ann Oncol; 2016 Aug; 27(8):1505-10. PubMed ID: 27407100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma".
    Piver MS
    Cancer Treat Rep; 1986 Dec; 70(12):1466. PubMed ID: 3791262
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
    Li GT
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):582-6. PubMed ID: 23141177
    [No Abstract]   [Full Text] [Related]  

  • 34. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group.
    Markman M
    Gynecol Oncol; 2011 Aug; 122(2):462; author reply 462-3. PubMed ID: 21620447
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of recurrent endodermal sinus tumor of the ovary associated with pregnancy.
    Tao T; Yang JX; Cao DY; Liu JT; Shen K
    Gynecol Oncol; 2011 Aug; 122(2):455-6. PubMed ID: 21600636
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of platinum-resistant ovarian cancer].
    Onishi Y; Nakamura T; Hatae M
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():554-9. PubMed ID: 15535307
    [No Abstract]   [Full Text] [Related]  

  • 37. A ten-year remission maintained by 6,272 mg (3,920 mg/m2) cumulative dose of cisplatin-based chemotherapy for recurrent epithelial ovarian cancer.
    Piver MS
    Eur J Gynaecol Oncol; 2001; 22(6):403-5. PubMed ID: 11874068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
    Munkarah A
    Nat Clin Pract Oncol; 2005 Apr; 2(4):188-9. PubMed ID: 16264930
    [No Abstract]   [Full Text] [Related]  

  • 39. Second-line therapy for ovarian cancer.
    Markman M
    Clin Adv Hematol Oncol; 2008 Jun; 6(6):421-2. PubMed ID: 18567987
    [No Abstract]   [Full Text] [Related]  

  • 40. [Chemotherapy for recurrent ovarian cancer].
    Nishimura H; Imamura K; Chang C
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1124-8. PubMed ID: 8751798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.